Q3 2025 Grail Inc Earnings Call Transcript
Key Points
- GRAIL Inc (GRAL) reported a 39% increase in Galleri test volumes and a 29% increase in revenue for the third quarter of 2025.
- The company announced a strategic collaboration with Samsung to commercialize the Galleri test in key Asian markets, including South Korea, Japan, and Singapore.
- GRAIL Inc (GRAL) completed a $325 million private placement, strengthening its balance sheet and extending its cash runway into 2030.
- Positive performance and safety results were shared from the PATHFINDER 2 study, showing a sevenfold increase in cancer detection rates when Galleri was added to recommended screenings.
- The SYMPLIFY study showed an increase in positive predictive value to 84.2% after extended follow-up, reinforcing the importance of proactive follow-up after a positive test result.
- GRAIL Inc (GRAL) reported a net loss of $89 million for the third quarter, although this was an improvement compared to the previous year.
- The company is facing seasonal fluctuations in test volumes, with lower volumes typically observed in the first and third quarters.
- There is uncertainty regarding the impact of recent or upcoming competition on GRAIL Inc (GRAL)'s commercial strategy.
- The NHS England decision not to accelerate the implementation of Galleri was due to the data not being exceptional enough, indicating challenges in gaining broader acceptance.
- The company is offering a $150 discount on Galleri tests, which could impact average selling prices and future revenue.
Good day, ladies and gentlemen, and welcome to the GRAIL third-quarter 2025 earnings call. (Operator Instructions) Please be advised that this conference call is being recorded.
GRAIL Investor Relations, please begin.
Thanks, operator, and thanks, everyone, for joining us today. On the call are Bob Ragusa, our Chief Executive Officer; Aaron Freidin, Chief Financial Officer; Josh Ofman, President; Sir Harpal Kumar, Chief Scientific Officer and President, International; and Andy Partridge, Chief Commercial Officer. We'll be making forward-looking statements on this call based on current expectations. It's our intent that all statements other than statements of historical fact, including statements regarding our anticipated financial results and commercial activity, will be covered by the Safe Harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933 as amended and Section 21 of the Securities Exchange Act of 1934 as amended.
Forward-looking statements are subject to risks
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
